Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc., listed on Nasdaq under the ticker BLUW, is the post-combination entity formed through the merger of Blue Water Acquisition Corp, a healthcare-focused blank check company, with Clarus Therapeutics, a specialty biopharmaceutical firm best known for its oral testosterone therapy JATENZO. Blue Water Acquisition Corp completed its initial public offering in 2020, targeting the life sciences and healthcare sector. The company filed this Form 10-Q with the SEC on August 16, 2021, reflecting quarterly financials for the period following the close of the de-SPAC transaction earlier that year. Clarus Therapeutics Holdings was an active post-merger reporting company at the time of filing. Sign up at SpacDesk for complete filing history, deal analytics, and sponsor data on BLUW and every tracked SPAC transaction.